105 related articles for article (PubMed ID: 9892992)
1. Preparation of a diagnostic antigen of human melanoma based on lymphocyte activation as measured by intracellular fluorescein fluorescence polarization.
Avtalion N; Avtalion R; Tirosh R; Sheinberg A; Weinreb A; Avinoach I; Deutsch M
Cancer Detect Prev; 1999; 23(1):64-71. PubMed ID: 9892992
[TBL] [Abstract][Full Text] [Related]
2. Detection of melanoma by monitoring the intracellular fluorescein fluorescence polarization changes in lymphocytes.
Merimsky O; Kaplan B; Deutsch M; Tirosh R; Weinreb A; Chaitchik S
Cancer Detect Prev; 1997; 21(2):167-77. PubMed ID: 9101078
[TBL] [Abstract][Full Text] [Related]
3. Decrease of intracellular fluorescein fluorescence polarization (IFFP) in human peripheral blood lymphocytes undergoing stimulation with phytohaemagglutinin (PHA), concanavalin A (ConA), pokeweed mitogen (PWM) and anti-CD3 antibody.
Eisenthal A; Marder O; Dotan D; Baron S; Lifschitz-Mercer B; Chaitchik S; Tirosh R; Weinreb A; Deutsch M
Biol Cell; 1996; 86(2-3):145-50. PubMed ID: 8893505
[TBL] [Abstract][Full Text] [Related]
4. Response of human lymphocytes to PHA and tumour-associated antigens as detected by fluorescence polarization.
Balding P; Light PA; Preece AW
Br J Cancer; 1980 Jan; 41(1):73-85. PubMed ID: 6153900
[TBL] [Abstract][Full Text] [Related]
5. Tumor-specific T-cell clones recognize different protein determinants of autologous human malignant melanoma cells.
Notter M; Schirrmacher V
Int J Cancer; 1990 May; 45(5):834-41. PubMed ID: 2159436
[TBL] [Abstract][Full Text] [Related]
6. Response of T lymphocytes to phytohaemagglutinin (PHA) and to cancer-tissue-associated antigens, measured by the intracellular fluorescence polarization technique (SCM test).
Orjasaeter H; Jordfald G; Svendsen I
Br J Cancer; 1979 Oct; 40(4):628-33. PubMed ID: 387060
[TBL] [Abstract][Full Text] [Related]
7. Characterization of lymphocytes in a patient with Wiskott-Aldrich syndrome: studies by fluorescence polarization.
Shiotsuki K; Hirata T; Ota M; Kimura K; Hiyoshi Y; Yamashita F; Yokoyama MM
J Clin Lab Immunol; 1989 Apr; 28(4):201-5. PubMed ID: 2628582
[TBL] [Abstract][Full Text] [Related]
8. Identification and characterization of a 14 kDa immunosuppressive protein derived from IIB-MEL-J, a human melanoma cell line.
Morvillo V; Bover L; Mordoh J
Cell Mol Biol (Noisy-le-grand); 1996 Jul; 42(5):779-95. PubMed ID: 8832109
[TBL] [Abstract][Full Text] [Related]
9. Dinitrophenyl-modified autologous melanoma vaccine induces a T cell response to hapten-modified, melanoma peptides.
Sato T; Bullock TN; Eisenlohr LC; Mastrangelo MJ; Berd D
Clin Immunol Immunopathol; 1997 Dec; 85(3):265-72. PubMed ID: 9400626
[TBL] [Abstract][Full Text] [Related]
10. In vivo activation of melanoma-specific CD8(+) T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells.
Speiser DE; Liénard D; Pittet MJ; Batard P; Rimoldi D; Guillaume P; Cerottini JC; Romero P
Eur J Immunol; 2002 Mar; 32(3):731-41. PubMed ID: 11870617
[TBL] [Abstract][Full Text] [Related]
11. Stimulation of tumor-reactive T lymphocytes using mixtures of synthetic peptides derived from tumor-associated antigens with diverse MHC binding affinities.
Riley JP; Rosenberg SA; Parkhurst MR
J Immunol Methods; 2003 May; 276(1-2):103-19. PubMed ID: 12738363
[TBL] [Abstract][Full Text] [Related]
12. Human melanoma cells transfected with the B7-2 co-stimulatory molecule induce tumor-specific CD8+ cytotoxic T lymphocytes in vitro.
Imro MA; Dellabona P; Manici S; Heltai S; Consogno G; Bellone M; Rugarli C; Protti MP
Hum Gene Ther; 1998 Jun; 9(9):1335-44. PubMed ID: 9650618
[TBL] [Abstract][Full Text] [Related]
13. Generation of Melan-A/MART-1-specific CD8+ cytotoxic T lymphocytes from human naive precursors: helper effect requirement for efficient primary cytotoxic T lymphocyte induction in vitro.
Ostankovitch M; Le Gal FA; Connan F; Chassin D; Choppin J; Guillet JG
Int J Cancer; 1997 Sep; 72(6):987-94. PubMed ID: 9378563
[TBL] [Abstract][Full Text] [Related]
14. Isolation of the melanoma-associated antigen p23 using antibody phage display.
Li J; Pereira S; Van Belle P; Tsui P; Elder D; Speicher D; Deen K; Linnenbach A; Somasundaram R; Swoboda R; Herlyn D
J Immunol; 2001 Jan; 166(1):432-8. PubMed ID: 11123321
[TBL] [Abstract][Full Text] [Related]
15. High avidity melanoma-reactive cytotoxic T lymphocytes are efficiently induced from peripheral blood lymphocytes on stimulation by peptide-pulsed melanoma cells.
Gervois N; Labarriere N; Le Guiner S; Pandolfino MC; Fonteneau JF; Guilloux Y; Diez E; Dreno B; Jotereau F
Clin Cancer Res; 2000 Apr; 6(4):1459-67. PubMed ID: 10778978
[TBL] [Abstract][Full Text] [Related]
16. Induction of melanoma antigen-specific cytotoxic T lymphocytes in vitro by stimulation with B7-expressing human melanoma cell lines.
Fenton RG; Turcovski-Corrales SM; Taub DD
J Immunother; 1998 Mar; 21(2):95-108. PubMed ID: 9551360
[TBL] [Abstract][Full Text] [Related]
17. Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides.
Salgaller ML; Afshar A; Marincola FM; Rivoltini L; Kawakami Y; Rosenberg SA
Cancer Res; 1995 Nov; 55(21):4972-9. PubMed ID: 7585538
[TBL] [Abstract][Full Text] [Related]
18. T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone.
Sensi M; Salvi S; Castelli C; Maccalli C; Mazzocchi A; Mortarini R; Nicolini G; Herlyn M; Parmiani G; Anichini A
J Exp Med; 1993 Oct; 178(4):1231-46. PubMed ID: 8376931
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity of the ALLAVGATK (gp100[17-25]) peptide in HLA-A3.1 melanoma patients.
Castelli C; Mazzocchi A; Rini F; Tarsini P; Rivoltini L; Maio M; Gallino G; Belli F; Parmiani G
Eur J Immunol; 1998 Apr; 28(4):1143-54. PubMed ID: 9565353
[TBL] [Abstract][Full Text] [Related]
20. Detection of lymphocyte stimulation by flow cytometry: differences in cells from patients with and without neoplasia.
Hartmann W; Sackmann E; Eisert WG; Eisert R; Fliedner TM
Biomedicine; 1980 Dec; 32(4):185-8. PubMed ID: 7470580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
